{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
Restrict the search for
aminosalicylic acid
to a specific field?
Status:
Investigational
Source:
NCT02195232: Phase 2/Phase 3 Interventional Completed Thromboembolism of Vein VTE in Colorectal Cancer
(2015)
Source URL:
Class (Stereo):
CHEMICAL (ABSOLUTE)
Targets:
Isoquercetin is a flavonoid, derivative of quercetin. It was isolated from various plant species including Ammothamnus Lehmanii, Caragana alaica, Cicer baldshuanicum, C. macroconthum, C. pungens, Euphorbia cyparissias, E. helioscapia, E. lathyris, E. lucida, E. purporata and others. It demonstrated radical scavenging activity, inhibitory effects on Na+/K+-ATPase and positive inotropic activity. It is protein disulfide isomerase (PDI) inhibitor. As a PDI inhibitor, this agent blocks PDI-mediated platelet activation, and fibrin generation, which prevents thrombus formation after vascular injury. Isoquercetin inhibited the replication of both influenza A and B viruses at the lowest effective concentration. Isoquercetin activates the ERK1/2-Nrf2 pathway and protects against cerebral ischemia-reperfusion injury in vivo and in vitro. It is being investigated for prevention of thromboembolism in selected cancer patients and as an anti-fatigue agent in kidney cancer patients treated with sunitinib.
Status:
Investigational
Source:
NCT01091532: Phase 1 Interventional Completed Phase 1
(2010)
Source URL:
Class (Stereo):
CHEMICAL (ABSOLUTE)
Pfizer was developing UK-396,082, an imidazole-propionic acid, as an oral treatment for thrombosis and pulmonary fibrosis. UK-396,082 is a potent and selective inhibitor of activated thrombin-activatable fibrinolysis inhibitor (activated TAFI; TAFIa) with Ki of 10 nM. UK-396,082 displays excellent selectivity over plasma carboxypeptidase N (>1,000-fold); exhibits antithrombotic efficacy in a rabbit model of venous thrombosis, yet has no effect on surgical bleeding in the rabbit; possesses excellent preclinical and clinical pharmacokinetic profile. UK-396,082 showed potential for the treatment of thrombosis and other fibrin-dependent diseases in humans, however its development was discontinued.
Class (Stereo):
CHEMICAL (ABSOLUTE)
Streptoniazid is a streptomycin derivative patented by Societe des usines chimiques de Rhone-Poulenc as antibiotic effective against tuberculosis.
Status:
Investigational
Source:
NCT00044070: Phase 2 Interventional Completed Cerebrovascular Accident
(2000)
Source URL:
Class (Stereo):
CHEMICAL (ACHIRAL)
Zonampanel (also known as YM872) was developed as selective, potent and highly water-soluble competitive alpha-amino-3-hydroxy-5-methylisoxazole-4-propionic acid (AMPA) receptor antagonist. Zonampanel possesses the neuroprotective effect against focal cerebral ischemia and participated in phase II clinical trials in acute stroke patients. However, because of the severe effects, including hallucinations, agitation, and catatonia the further studied were terminated.
Status:
Investigational
Source:
NCT00945282: Phase 2 Interventional Completed Infection, Human Immunodeficiency Virus
(2009)
Source URL:
Class (Stereo):
CHEMICAL (ABSOLUTE)
Status:
Investigational
Source:
NCT00440492: Phase 1 Interventional Completed Arthritis, Rheumatoid
(2006)
Source URL:
Class (Stereo):
CHEMICAL (ACHIRAL)
Giripladib (PLA 695) is a Cytosolic phospholipase A2 (cPLA2) inhibitor. cPLA2 is associated with tumor progression and radioresistance in mouse tumor models. In these models, treatment with giripladib attenuates radiation induced increases of phospho-ERK and phospho-Akt in endothelial cells. Combined with irradiation, giripladib reduces migration and proliferation in endothelial cells (HUVEC & bEND3) and induces cell death and attenuated invasion by tumor cells (LLC &A549). The combination treatment of giripladib and irradiation also delayes growth in both LLC and A549 tumors and results in reduced tumor vasculature. Phase I studies have been conducted to test the gastrointestinal safety of giripladib, and potential pharmacokinetic interaction with other compounds. A phase II study was terminated.
Status:
Investigational
Source:
INN:mexrenoate potassium [INN]
Source URL:
Class (Stereo):
CHEMICAL (ABSOLUTE)
Mexrenoate potassium is an aldosterone antagonist, which was developed as an antihypertensive agent. However, this drug has never been marketed.
Class (Stereo):
CHEMICAL (ACHIRAL)
Nifurthiazole, a 5-nitrofuran derivative, is an antibacterial and antiprotozoal agent, it is active against Trypanosoma. It was also used for controlling Salmonella choleraesuis in swine. The mode of action of 5-nitrofuran analogues is based on red-ox biotransformation.
Status:
Investigational
Class (Stereo):
CHEMICAL (ACHIRAL)
Uredepa, a thiotepa derivative, is a antineoplastic, alkylating agent. It has also been used experimentally as an insect chemosterilant.
Status:
Investigational
Source:
INN:iocanlidic acid (¹²³I) [INN]
Source URL:
Class (Stereo):
CHEMICAL (ACHIRAL)
Iocanlidic Acid I-123 is a radiolabeled phenylfatty acid derivative studied as a diagnostic agent for myocardial imaging
